• Company
    • Company Overview
    • Team
    • Board
  • Approach
    • Approach
    • Opioid Induced Respiratory Depression
    • Paediatric
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • News
  • Careers
  • Contact
PneumoWave PneumoWave
  • Company
    • Company Overview
    • Team
    • Board
  • Approach
    • Approach
    • Opioid Induced Respiratory Depression
    • Paediatric
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • News
  • Careers
  • Contact
PneumoWave

Dr Gary Cooney appointed as Mental Health Lead

Home / News / Press Release / Dr Gary Cooney appointed as Mental Health Lead
inPress Release

Digital health company PneumoWave appoints Dr Gary Cooney as Mental Health Lead as it targets respiratory depression among patients taking opioids

PUBLISHED: APRIL 19, 2022

Digital health company PneumoWave today announced the appointment of Dr Gary Cooney as Mental Health Lead, with responsibility for the planning and execution of addiction and other mental health-related treatment studies using PneumoWave’s technology platform for diagnosis and monitoring of respiratory changes.

Gary is a medical doctor and consultant psychiatrist with extensive experience working with addiction and mental health issues in the NHS and private sector. Following a BA at Harvard, Gary studied medicine at Edinburgh University.

“Gary brings extensive expertise in the field of psychiatry as we seek to integrate our technology into routine use within addictions and mental health treatment programs” said CEO Bruce Henderson. “He will also contribute significantly to the review of datasets from our clinical research program, now underway in Dundee, Glasgow and King’s College, London, as we evaluate both physiological and behavioural data outputs to develop highly effective and easy to use solutions to reduce deaths from opioids.”

About PneumoWave:

PneumoWave is a development stage digital health company based in Scotland and the US. The company’s proprietary digital technology provides real-time physiological data and patient-centric digital biomarkers with the core focus of preventing deaths and reducing hospital admissions from respiratory causes. Performance characteristics are not yet established.

MEDIA CONTACT:

Richard Hayhurst, RHA PR
Tel +44 (0) 7711 821 527
richard@rhapr.eu

Dr Gary Cooney
Dr Gary Cooney
  • Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
    Previous PostDundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
  • Next PostPneumoWave Featured in the Scotsman
    Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths

Related Posts

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform
Press Release

PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform

PneumoWave Featured in the Scotsman
Press Release

PneumoWave Featured in the Scotsman

Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
Press Release

Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths

PneumoWave & King’s College London Collaborate in Clinical Trial
Press Release

PneumoWave & King’s College London Collaborate in Clinical Trial

pneumowave logo colour

About PneumoWave

Contact

Privacy Policy

PneumoWave’s technology is currently undergoing development and evaluation in clinical trials. Performance characteristics have yet to be established.

Website by genapse